Evidence map›Paper›PMID 26911679›Full record

ArticleScientific reports2016

Epigenetic Silencing of the Key Antioxidant Enzyme Catalase in Karyotypically Abnormal Human Pluripotent Stem Cells.

Mikko Konki, Kalyan Pasumarthy, Maia Malonzo, Annele Sainio, Cristina Valensisi, Mirva Söderström, Maheswara Reddy Emani, Aki Stubb, Elisa Närvä, Bishwa Ghimire and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Targeting catalase in cancer.Redox biology · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Reduction-oxidation (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutics.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Mikko KonkiTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Kalyan PasumarthyTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Maia MalonzoDepartment of Information and Computer Science, Aalto University School of Science, Helsinki, Finland.
Annele SainioDepartment of Medical Biochemistry and Genetics, University of Turku, and Department of Medicine, Division of Endocrinology, Turku University Hospital, Turku, Finland.
Cristina ValensisiTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Mirva SöderströmDepartment of Pathology, Turku University Hospital, University of Turku, Turku, Finland.
Maheswara Reddy EmaniTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Aki StubbTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Elisa NärväTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Bishwa GhimireTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Asta LaihoTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Hannu JärveläinenDepartment of Medical Biochemistry and Genetics, University of Turku, and Department of Medicine, Division of Endocrinology, Turku University Hospital, Turku, Finland.
Riitta LahesmaaTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Harri LähdesmäkiDepartment of Information and Computer Science, Aalto University School of Science, Helsinki, Finland.
R David HawkinsTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Riikka J LundTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
University of Turku · FIÅbo Akademi University · FITurku Centre for Biotechnology · FIAalto University · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenomic regulation is likely to be important in the maintenance of genomic integrity of human pluripotent stem cells, however, the mechanisms are unknown. We explored the epigenomes and transcriptomes of human pluripotent stem cells before and after spontaneous transformation to abnormal karyotypes and in correlation to cancer cells. Our results reveal epigenetic silencing of Catalase, a key regulator of oxidative stress and DNA damage control in abnormal cells. Our findings provide novel insight into the mechanisms associated with spontaneous transformation of human pluripotent stem cells towards malignant fate. The same mechanisms may control the genomic stability of cells in somatic tissues.

Indexed as

Abnormal KaryotypeGene SilencingCase-Control StudiesCatalaseCell LineHumansMaleOxidative StressPluripotent Stem CellsTesticular NeoplasmsTranscriptomeCatalase

Identifiers

PMID26911679
PMCPMC4766493
OpenAlexW2283996325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.